期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

P-糖蛋白相关的药物不良反应研究进展 被引量：4

Progress on P-glycoprotein related adverse drug reactions
下载PDF
导出
摘要 P-糖蛋白(P-glycoprotein,P-gp)是一种三磷酸腺苷(adenosine triphosphate,ATP)依赖的外排型药物转运蛋白,对药物的体内过程起重要调控作用。由P-gp介导的药物相互作用及多药耐药蛋白1(multidrug resistance protein 1,MDR1)基因单核苷酸多态性(single nucleotide polymorphisms,SNPs)引起的个体化差异是P-gp底物在临床用药过程中产生不良反应的主要原因。本文对P-gp相关的不良反应研究进展进行综述,为提高相关药物的临床疗效及安全性提供依据。 P-glycoprotein （P-gp）,an adenosine triphosphate （ATP） dependent drug efflux transporter,plays an important role in several intracorporal processes of medications.The adverse drug reactions （ADRs） caused by P-gp substrates are mainly due to the drug interactions mediated by P-gp and the individual difference results from single nucleotide polymorphisms （SNPs） of MDR1 gene.This review reveals the research progress on P-gp related ADRs in order to improve therapeutic effect and safety of clinical medications.
作者 陆蕴红 戴佩芳 叶岩荣 沈赟
机构地区 复旦大学附属中山医院药剂科
出处 《复旦学报（医学版）》 CAS CSCD 北大核心 2016年第4期495-499,共5页 Fudan University Journal of Medical Sciences
基金 复旦大学附属中山医院管理科学基金(2015ZSGL-005)~~
关键词 P-糖蛋白 药物不良反应 基因多态性 药物相互作用 P-glycoprotein adverse drug reactions gene polymorphisms drug interaction
分类号 R968 [医药卫生—药理学] R969.2 [医药卫生—药理学]
  • 相关文献

参考文献27

  • 1JULIANO RL, LING V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants[J]. Biochim Biophys Acta, 1976,455 ( 1 ) : 152-162.
  • 2LING X, HE Y, ZHANG G, et al. Increased P- glycoprotein expression in mitochondria is related to acquired multidrug resistance in human hepatoma cells depleted of mitochondrial DNA[J]. Int J Oncol, 2(/12,40 (1):109 -118.
  • 3SUGAWARA I. Expression and functions of P- glycoprotein (MDR1 gene product) in normal and malignant tissues [J]. Acta Pathol Jpn, 1990, 40 (8) : 545-553.
  • 4SILVERMAN JA. Multidrug-resistance transporters[J]. Pharm Biotechnol, 1999,12 : 353-386.
  • 5BALAYSSAC D, AUTHIER N, CAYRE A, et al. Does inhibition of P-glycoprotein lead to drug-drug interactions.'?[J]. Toxicol Lett ,2005,156 (3) :319-329.
  • 6RAAD I, TERREUX R, RICHOMME P, et al. Structure- activity relationship of natural and synthetic coumarins inhibiting the multidrug transporter P-glycoprotein[J]. Bioorg Med Chem ,2006,14 (20) :6979-6987.
  • 7SHITAN N, TANAKA M, TERAI K, et al. Human MDR1 and MRP1 recognize berberine as their transport substrate[J]. Biosci Biotechnol Biochem, 2007,71 ( 1 ) : 242-245.
  • 8CHOO EF, LEAKE B, WANDEL C, et al. Pharmacological inhibition of P glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes [J].Drug Metab Dispos, 2000,28 (6) : 655-660.
  • 9HAMMAN MA, BRUCE MA, HAEHNER-DANIELSBD, et al. The effect of rifampin administration on the disposition of fexofenadine[J]. Clin Pharmacol Ther, 2001,69 (3) :114- 121.
  • 10IQBAL M, GIBB W, MATTHEWS SG. Corticosteroid regulation of P-glyeoprotein in the developing blood brain barrier[J].Endocrinology ,2011,152 (3):1067-1079.

二级参考文献13

  • 1王丹,克晓燕,王晶,徐芳,胡永芳.MDR1基因多态性与急性髓细胞白血病化学疗法结果的相关性研究[J].中华医学杂志,2007,87(20):1384-1388. 被引量：3
  • 2Hoffmeyer S, Burk O, yon Richter O, et al. Functional polymorphisms of the human muLtidrug-resistance gene: muLtiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo[J]. Proc National Academy Sci,2000,97(7):3473- 3478.
  • 3Hitzl M, Drescher S, van der Kuip H, et al. The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P- glycoprotein substrate rhodamine 123 from CD56+ natural killer cells [J]. Pharmacogenetics,2001,11 (4):293-298.
  • 4Cascorbi I, Gerloff T, Johne A, et al. Frequency of single nueleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subj ec ts[J]. Clinical Pharmacology Therapy,2001,69 ( 3 ): 169-174.
  • 5Illmer T, SchuLer U S, Thiede C, et al. MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients[J]. Cancer Research, 2002, 62 (17):4955-4962.
  • 6Lewin B, GENE [M] 8th ed. New York, PEARSON PRENTICE HALL, 2004 : 995.
  • 7Ameyaw M R F, Li T. MDRlpharmacogeneics:frequency of the C3435T mutation in exon 26 is significantly influenced by ethnicity [J]. Pharmacogenetic, 2001,11(3) :217-221.
  • 8Shen L X, Basilion J P, Stanton V P. Single-nucleotide polymorphisms can cause different structural folds of mRNA [J]. Proeedings of the National Academy of Sciences, 1999, 96(14):7871-7876.
  • 9Kim DH PP, Sohn S K. MuLtidrug resistance-1 gene polymerphisms associated with treatment outcomes in de novo acute myeloid leukemia [J]. International J Caner, 2006, 118 (9):2195-2201.
  • 10Utecht KN, Hiles JJ, Kolesar J. Effects of genetic polymorphisms on the pharmacokinetics of calciuneurin inhibitors[ J]. Am J Health Syst Pharm, 2006 , 63 : 2340 - 2348.

共引文献9

同被引文献68

引证文献4

二级引证文献6

复旦学报（医学版）
2016年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部